Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 395

1.

Memory Inflation Drives Tissue-Resident Memory CD8+ T Cell Maintenance in the Lung After Intranasal Vaccination With Murine Cytomegalovirus.

Morabito KM, Ruckwardt TJ, Bar-Haim E, Nair D, Moin SM, Redwood AJ, Price DA, Graham BS.

Front Immunol. 2018 Aug 14;9:1861. doi: 10.3389/fimmu.2018.01861. eCollection 2018.

2.

The Morphology and Assembly of Respiratory Syncytial Virus Revealed by Cryo-Electron Tomography.

Ke Z, Dillard RS, Chirkova T, Leon F, Stobart CC, Hampton CM, Strauss JD, Rajan D, Rostad CA, Taylor JV, Yi H, Shah R, Jin M, Hartert TV, Peebles RS Jr, Graham BS, Moore ML, Anderson LJ, Wright ER.

Viruses. 2018 Aug 20;10(8). pii: E446. doi: 10.3390/v10080446.

3.

Breast milk prefusion F IgG as a correlate of protection against respiratory syncytial virus acute respiratory illness.

Mazur NI, Horsley N, Englund JA, Nederend M, Magaret A, Kumar A, Jacobino SR, Xander H, Khatry SK, LeClerq SC, Steinhoff MC, Tielsch JM, Katz J, Graham BS, Bont LJ, Leusen JHW, Chu HY.

J Infect Dis. 2018 Aug 10. doi: 10.1093/infdis/jiy477. [Epub ahead of print]

PMID:
30107412
4.

The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates.

Mazur NI, Higgins D, Nunes MC, Melero JA, Langedijk AC, Horsley N, Buchholz UJ, Openshaw PJ, McLellan JS, Englund JA, Mejias A, Karron RA, Simões EA, Knezevic I, Ramilo O, Piedra PA, Chu HY, Falsey AR, Nair H, Kragten-Tabatabaie L, Greenough A, Baraldi E, Papadopoulos NG, Vekemans J, Polack FP, Powell M, Satav A, Walsh EE, Stein RT, Graham BS, Bont LJ; Respiratory Syncytial Virus Network (ReSViNET) Foundation.

Lancet Infect Dis. 2018 Oct;18(10):e295-e311. doi: 10.1016/S1473-3099(18)30292-5. Epub 2018 Jun 18. Review. Erratum in: Lancet Infect Dis. 2018 Jul 25;:.

PMID:
29914800
5.

Use of Hemagglutinin Stem Probes Demonstrate Prevalence of Broadly Reactive Group 1 Influenza Antibodies in Human Sera.

Yassine HM, McTamney PM, Boyington JC, Ruckwardt TJ, Crank MC, Smatti MK, Ledgerwood JE, Graham BS.

Sci Rep. 2018 Jun 5;8(1):8628. doi: 10.1038/s41598-018-26538-7.

6.

Novel Vaccine Technologies: Essential Components of an Adequate Response to Emerging Viral Diseases.

Graham BS, Mascola JR, Fauci AS.

JAMA. 2018 Apr 10;319(14):1431-1432. doi: 10.1001/jama.2018.0345. No abstract available.

PMID:
29566112
7.

Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on MERS-CoV Spike to avoid neutralization escape.

Wang L, Shi W, Chappell JD, Joyce MG, Zhang Y, Kanekiyo M, Becker MM, van Doremalen N, Fischer R, Wang N, Corbett KS, Choe M, Mason RD, Van Galen JG, Zhou T, Saunders KO, Tatti KM, Haynes LM, Kwong PD, Modjarrad K, Kong WP, McLellan JS, Denison MR, Munster VJ, Mascola JR, Graham BS.

J Virol. 2018 Mar 7. pii: JVI.02002-17. doi: 10.1128/JVI.02002-17. [Epub ahead of print]

PMID:
29514901
8.

A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases.

Erbelding EJ, Post DJ, Stemmy EJ, Roberts PC, Augustine AD, Ferguson S, Paules CI, Graham BS, Fauci AS.

J Infect Dis. 2018 Jul 2;218(3):347-354. doi: 10.1093/infdis/jiy103.

PMID:
29506129
9.

Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens.

Georgiev IS, Joyce MG, Chen RE, Leung K, McKee K, Druz A, Van Galen JG, Kanekiyo M, Tsybovsky Y, Yang ES, Yang Y, Acharya P, Pancera M, Thomas PV, Wanninger T, Yassine HM, Baxa U, Doria-Rose NA, Cheng C, Graham BS, Mascola JR, Kwong PD.

ACS Infect Dis. 2018 May 11;4(5):788-796. doi: 10.1021/acsinfecdis.7b00192. Epub 2018 Mar 6.

PMID:
29451984
10.

Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation.

Goodwin E, Gilman MSA, Wrapp D, Chen M, Ngwuta JO, Moin SM, Bai P, Sivasubramanian A, Connor RI, Wright PF, Graham BS, McLellan JS, Walker LM.

Immunity. 2018 Feb 20;48(2):339-349.e5. doi: 10.1016/j.immuni.2018.01.005. Epub 2018 Feb 3.

11.

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.

Gaudinski MR, Coates EE, Houser KV, Chen GL, Yamshchikov G, Saunders JG, Holman LA, Gordon I, Plummer S, Hendel CS, Conan-Cibotti M, Lorenzo MG, Sitar S, Carlton K, Laurencot C, Bailer RT, Narpala S, McDermott AB, Namboodiri AM, Pandey JP, Schwartz RM, Hu Z, Koup RA, Capparelli E, Graham BS, Mascola JR, Ledgerwood JE; VRC 606 Study Team.

PLoS Med. 2018 Jan 24;15(1):e1002493. doi: 10.1371/journal.pmed.1002493. eCollection 2018 Jan.

12.

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial.

Fong Y, Shen X, Ashley VC, Deal A, Seaton KE, Yu C, Grant SP, Ferrari G, deCamp AC, Bailer RT, Koup RA, Montefiori D, Haynes BF, Sarzotti-Kelsoe M, Graham BS, Carpp LN, Hammer SM, Sobieszczyk M, Karuna S, Swann E, DeJesus E, Mulligan M, Frank I, Buchbinder S, Novak RM, McElrath MJ, Kalams S, Keefer M, Frahm NA, Janes HE, Gilbert PB, Tomaras GD.

J Infect Dis. 2018 Mar 28;217(8):1280-1288. doi: 10.1093/infdis/jiy008.

13.

Functional interrogation and mining of natively paired human VH:VL antibody repertoires.

Wang B, DeKosky BJ, Timm MR, Lee J, Normandin E, Misasi J, Kong R, McDaniel JR, Delidakis G, Leigh KE, Niezold T, Choi CW, Viox EG, Fahad A, Cagigi A, Ploquin A, Leung K, Yang ES, Kong WP, Voss WN, Schmidt AG, Moody MA, Ambrozak DR, Henry AR, Laboune F, Ledgerwood JE, Graham BS, Connors M, Douek DC, Sullivan NJ, Ellington AD, Mascola JR, Georgiou G.

Nat Biotechnol. 2018 Feb;36(2):152-155. doi: 10.1038/nbt.4052. Epub 2018 Jan 8.

14.

The Zika virus envelope protein glycan loop regulates virion antigenicity.

Goo L, DeMaso CR, Pelc RS, Ledgerwood JE, Graham BS, Kuhn RJ, Pierson TC.

Virology. 2018 Feb;515:191-202. doi: 10.1016/j.virol.2017.12.032. Epub 2018 Jan 2.

PMID:
29304471
15.

Recent progress in immune-based interventions to prevent HIV-1 transmission to children.

Voronin Y, Jani I, Graham BS, Cunningham CK, Mofenson LM, Musoke PM, Permar SR, Scarlatti G.

J Int AIDS Soc. 2017 Dec;20(4). doi: 10.1002/jia2.25038.

16.

Zika Virus Vaccine Development.

Morabito KM, Graham BS.

J Infect Dis. 2017 Dec 16;216(suppl_10):S957-S963. doi: 10.1093/infdis/jix464.

PMID:
29267918
17.

An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial.

DeZure AD, Coates EE, Hu Z, Yamshchikov GV, Zephir KL, Enama ME, Plummer SH, Gordon IJ, Kaltovich F, Andrews S, McDermott A, Crank MC, Koup RA, Schwartz RM, Bailer RT, Sun X, Mascola JR, Tumpey TM, Graham BS, Ledgerwood JE.

NPJ Vaccines. 2017 Jun 1;2:15. doi: 10.1038/s41541-017-0016-6. eCollection 2017.

18.

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.

Gilbert PB, Juraska M, deCamp AC, Karuna S, Edupuganti S, Mgodi N, Donnell DJ, Bentley C, Sista N, Andrew P, Isaacs A, Huang Y, Zhang L, Capparelli E, Kochar N, Wang J, Eshleman SH, Mayer KH, Magaret CA, Hural J, Kublin JG, Gray G, Montefiori DC, Gomez MM, Burns DN, McElrath J, Ledgerwood J, Graham BS, Mascola JR, Cohen M, Corey L.

Stat Commun Infect Dis. 2017 Jan;9(1). pii: 20160001. doi: 10.1515/scid-2016-0001. Epub 2017 Jun 6.

19.

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.

Gaudinski MR, Houser KV, Morabito KM, Hu Z, Yamshchikov G, Rothwell RS, Berkowitz N, Mendoza F, Saunders JG, Novik L, Hendel CS, Holman LA, Gordon IJ, Cox JH, Edupuganti S, McArthur MA, Rouphael NG, Lyke KE, Cummings GE, Sitar S, Bailer RT, Foreman BM, Burgomaster K, Pelc RS, Gordon DN, DeMaso CR, Dowd KA, Laurencot C, Schwartz RM, Mascola JR, Graham BS, Pierson TC, Ledgerwood JE, Chen GL; VRC 319; VRC 320 study teams.

Lancet. 2018 Feb 10;391(10120):552-562. doi: 10.1016/S0140-6736(17)33105-7. Epub 2017 Dec 5.

PMID:
29217376
20.

Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic.

Graham BS, Sullivan NJ.

Nat Immunol. 2018 Jan;19(1):20-28. doi: 10.1038/s41590-017-0007-9. Epub 2017 Dec 14. Review.

PMID:
29199281
21.

Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein.

Tian D, Battles MB, Moin SM, Chen M, Modjarrad K, Kumar A, Kanekiyo M, Graepel KW, Taher NM, Hotard AL, Moore ML, Zhao M, Zheng ZZ, Xia NS, McLellan JS, Graham BS.

Nat Commun. 2017 Nov 30;8(1):1877. doi: 10.1038/s41467-017-01858-w.

22.

Corrigendum: Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state.

Rossey I, Gilman MSA, Kabeche SC, Sedeyn K, Wrapp D, Kanekiyo M, Chen M, Mas V, Spitaels J, Melero JA, Graham BS, Schepens B, McLellan JS, Saelens X.

Nat Commun. 2017 Nov 29;8:16165. doi: 10.1038/ncomms16165.

23.

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.

deCamp AC, Rolland M, Edlefsen PT, Sanders-Buell E, Hall B, Magaret CA, Fiore-Gartland AJ, Juraska M, Carpp LN, Karuna ST, Bose M, LePore S, Miller S, O'Sullivan A, Poltavee K, Bai H, Dommaraju K, Zhao H, Wong K, Chen L, Ahmed H, Goodman D, Tay MZ, Gottardo R, Koup RA, Bailer R, Mascola JR, Graham BS, Roederer M, O'Connell RJ, Michael NL, Robb ML, Adams E, D'Souza P, Kublin J, Corey L, Geraghty DE, Frahm N, Tomaras GD, McElrath MJ, Frenkel L, Styrchak S, Tovanabutra S, Sobieszczyk ME, Hammer SM, Kim JH, Mullins JI, Gilbert PB.

PLoS One. 2017 Nov 17;12(11):e0185959. doi: 10.1371/journal.pone.0185959. eCollection 2017.

24.

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.

Mayer KH, Seaton KE, Huang Y, Grunenberg N, Isaacs A, Allen M, Ledgerwood JE, Frank I, Sobieszczyk ME, Baden LR, Rodriguez B, Van Tieu H, Tomaras GD, Deal A, Goodman D, Bailer RT, Ferrari G, Jensen R, Hural J, Graham BS, Mascola JR, Corey L, Montefiori DC; HVTN 104 Protocol Team; and the NIAID HIV Vaccine Trials Network.

PLoS Med. 2017 Nov 14;14(11):e1002435. doi: 10.1371/journal.pmed.1002435. eCollection 2017 Nov.

25.

Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus.

Sastry M, Zhang B, Chen M, Joyce MG, Kong WP, Chuang GY, Ko K, Kumar A, Silacci C, Thom M, Salazar AM, Corti D, Lanzavecchia A, Taylor G, Mascola JR, Graham BS, Kwong PD.

PLoS One. 2017 Oct 26;12(10):e0186854. doi: 10.1371/journal.pone.0186854. eCollection 2017.

26.

Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans.

Grifoni A, Pham J, Sidney J, O'Rourke PH, Paul S, Peters B, Martini SR, de Silva AD, Ricciardi MJ, Magnani DM, Silveira CGT, Maestri A, Costa PR, de-Oliveira-Pinto LM, de Azeredo EL, Damasco PV, Phillips E, Mallal S, de Silva AM, Collins M, Durbin A, Diehl SA, Cerpas C, Balmaseda A, Kuan G, Coloma J, Harris E, Crowe JE Jr, Stone M, Norris PJ, Busch M, Vivanco-Cid H, Cox J, Graham BS, Ledgerwood JE, Turtle L, Solomon T, Kallas EG, Watkins DI, Weiskopf D, Sette A.

J Virol. 2017 Oct 4. pii: JVI.01469-17. doi: 10.1128/JVI.01469-17. [Epub ahead of print]

27.

A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage.

Shan C, Muruato AE, Jagger BW, Richner J, Nunes BTD, Medeiros DBA, Xie X, Nunes JGC, Morabito KM, Kong WP, Pierson TC, Barrett AD, Weaver SC, Rossi SL, Vasconcelos PFC, Graham BS, Diamond MS, Shi PY.

Nat Commun. 2017 Sep 22;8(1):676. doi: 10.1038/s41467-017-00737-8.

28.

Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.

Liu X, Liang B, Ngwuta J, Liu X, Surman S, Lingemann M, Kwong PD, Graham BS, Collins PL, Munir S.

J Virol. 2017 Oct 27;91(22). pii: e01101-17. doi: 10.1128/JVI.01101-17. Print 2017 Nov 15.

29.

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.

Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, Cottrell CA, Becker MM, Wang L, Shi W, Kong WP, Andres EL, Kettenbach AN, Denison MR, Chappell JD, Graham BS, Ward AB, McLellan JS.

Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357. doi: 10.1073/pnas.1707304114. Epub 2017 Aug 14.

30.

HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques.

Han Q, Williams WB, Saunders KO, Seaton KE, Wiehe KJ, Vandergrift N, Von Holle TA, Trama AM, Parks RJ, Luo K, Gurley TC, Kepler TB, Marshall DJ, Montefiori DC, Sutherland LL, Alam MS, Whitesides JF, Bowman CM, Permar SR, Graham BS, Mascola JR, Seed PC, Van Rompay KKA, Tomaras GD, Moody MA, Haynes BF.

J Virol. 2017 Oct 13;91(21). pii: e00923-17. doi: 10.1128/JVI.00923-17. Print 2017 Nov 1.

31.

Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans.

Andrews SF, Joyce MG, Chambers MJ, Gillespie RA, Kanekiyo M, Leung K, Yang ES, Tsybovsky Y, Wheatley AK, Crank MC, Boyington JC, Prabhakaran MS, Narpala SR, Chen X, Bailer RT, Chen G, Coates E, Kwong PD, Koup RA, Mascola JR, Graham BS, Ledgerwood JE, McDermott AB.

Sci Immunol. 2017 Jul 14;2(13). pii: eaan2676. doi: 10.1126/sciimmunol.aan2676.

PMID:
28783708
32.

Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Immunogenetic Considerations Underlying B-Cell Biology in the Development of a Pan-Subtype Influenza A Vaccine Targeting the Hemagglutinin Stem.

Andrews SF, Graham BS, Mascola JR, McDermott AB.

Cold Spring Harb Perspect Biol. 2018 Jul 2;10(7). pii: a029413. doi: 10.1101/cshperspect.a029413. Review.

PMID:
28663207
33.

Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.

Liang B, Ngwuta JO, Surman S, Kabatova B, Liu X, Lingemann M, Liu X, Yang L, Herbert R, Swerczek J, Chen M, Moin SM, Kumar A, McLellan JS, Kwong PD, Graham BS, Collins PL, Munir S.

J Virol. 2017 Jul 12;91(15). pii: e00189-17. doi: 10.1128/JVI.00189-17. Print 2017 Aug 1.

34.

Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater In Vivo Protection than the Murine Precursor of Palivizumab.

Zhao M, Zheng ZZ, Chen M, Modjarrad K, Zhang W, Zhan LT, Cao JL, Sun YP, McLellan JS, Graham BS, Xia NS.

J Virol. 2017 Jul 12;91(15). pii: e00176-17. doi: 10.1128/JVI.00176-17. Print 2017 Aug 1.

35.

Vaccine development for respiratory syncytial virus.

Graham BS.

Curr Opin Virol. 2017 Apr;23:107-112. doi: 10.1016/j.coviro.2017.03.012. Epub 2017 May 16. Review.

36.

Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion Protein.

Leemans A, De Schryver M, Van der Gucht W, Heykers A, Pintelon I, Hotard AL, Moore ML, Melero JA, McLellan JS, Graham BS, Broadbent L, Power UF, Caljon G, Cos P, Maes L, Delputte P.

J Virol. 2017 Jun 26;91(14). pii: e00184-17. doi: 10.1128/JVI.00184-17. Print 2017 Jul 15.

37.

Neonatal mice possess two phenotypically and functionally distinct lung-migratory CD103+ dendritic cell populations following respiratory infection.

Ruckwardt TJ, Morabito KM, Bar-Haim E, Nair D, Graham BS.

Mucosal Immunol. 2018 Jan;11(1):186-198. doi: 10.1038/mi.2017.28. Epub 2017 Apr 5.

38.

Lymph Node Activation by PET/CT Following Vaccination With Licensed Vaccines for Human Papillomaviruses.

Coates EE, Costner PJ, Nason MC, Herrin DM, Conant S, Herscovitch P, Sarwar UN, Holman L, Mitchell J, Yamshchikov G, Koup RA, Graham BS, Millo CM, Ledgerwood JE; VRC 900 Study Team.

Clin Nucl Med. 2017 May;42(5):329-334. doi: 10.1097/RLU.0000000000001603.

PMID:
28288041
39.

Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection.

Lyke KE, Ishizuka AS, Berry AA, Chakravarty S, DeZure A, Enama ME, James ER, Billingsley PF, Gunasekera A, Manoj A, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, Kc N, Murshedkar T, Mendoza FH, Gordon IJ, Zephir KL, Holman LA, Plummer SH, Hendel CS, Novik L, Costner PJ, Saunders JG, Berkowitz NM, Flynn BJ, Nason MC, Garver LS, Laurens MB, Plowe CV, Richie TL, Graham BS, Roederer M, Sim BK, Ledgerwood JE, Hoffman SL, Seder RA.

Proc Natl Acad Sci U S A. 2017 Mar 7;114(10):2711-2716. doi: 10.1073/pnas.1615324114. Epub 2017 Feb 21.

40.

Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.

Janes HE, Cohen KW, Frahm N, De Rosa SC, Sanchez B, Hural J, Magaret CA, Karuna S, Bentley C, Gottardo R, Finak G, Grove D, Shen M, Graham BS, Koup RA, Mulligan MJ, Koblin B, Buchbinder SP, Keefer MC, Adams E, Anude C, Corey L, Sobieszczyk M, Hammer SM, Gilbert PB, McElrath MJ.

J Infect Dis. 2017 May 1;215(9):1376-1385. doi: 10.1093/infdis/jix086.

41.

Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state.

Rossey I, Gilman MS, Kabeche SC, Sedeyn K, Wrapp D, Kanekiyo M, Chen M, Mas V, Spitaels J, Melero JA, Graham BS, Schepens B, McLellan JS, Saelens X.

Nat Commun. 2017 Feb 13;8:14158. doi: 10.1038/ncomms14158. Erratum in: Nat Commun. 2017 Nov 29;8:16165.

42.

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination.

Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R, Wagner W, Granados A, Greenhouse J, Walker M, Willis E, Yu JS, McGee CE, Sempowski GD, Mui BL, Tam YK, Huang YJ, Vanlandingham D, Holmes VM, Balachandran H, Sahu S, Lifton M, Higgs S, Hensley SE, Madden TD, Hope MJ, Karikó K, Santra S, Graham BS, Lewis MG, Pierson TC, Haynes BF, Weissman D.

Nature. 2017 Mar 9;543(7644):248-251. doi: 10.1038/nature21428. Epub 2017 Feb 2.

43.

Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors.

Gilman MS, Castellanos CA, Chen M, Ngwuta JO, Goodwin E, Moin SM, Mas V, Melero JA, Wright PF, Graham BS, McLellan JS, Walker LM.

Sci Immunol. 2016 Dec 16;1(6). pii: eaaj1879. doi: 10.1126/sciimmunol.aaj1879. Epub 2016 Dec 9.

44.

A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation.

Stobart CC, Rostad CA, Ke Z, Dillard RS, Hampton CM, Strauss JD, Yi H, Hotard AL, Meng J, Pickles RJ, Sakamoto K, Lee S, Currier MG, Moin SM, Graham BS, Boukhvalova MS, Gilbert BE, Blanco JC, Piedra PA, Wright ER, Moore ML.

Nat Commun. 2016 Dec 21;7:13916. doi: 10.1038/ncomms13916.

45.

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.

Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, Salantes DB, Seamon CA, Scheinfeld B, Kwan RW, Learn GH, Proschan MA, Kreider EF, Blazkova J, Bardsley M, Refsland EW, Messer M, Clarridge KE, Tustin NB, Madden PJ, Oden K, O'Dell SJ, Jarocki B, Shiakolas AR, Tressler RL, Doria-Rose NA, Bailer RT, Ledgerwood JE, Capparelli EV, Lynch RM, Graham BS, Moir S, Koup RA, Mascola JR, Hoxie JA, Fauci AS, Tebas P, Chun TW.

N Engl J Med. 2016 Nov 24;375(21):2037-2050. Epub 2016 Nov 9.

46.

Chikungunya in the Americas: Recommendations and Conclusions.

Graham BS, Repik PM, Yactayo S.

J Infect Dis. 2016 Dec 15;214(suppl 5):S510-S513.

47.

Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.

DeZure AD, Berkowitz NM, Graham BS, Ledgerwood JE.

J Infect Dis. 2016 Dec 15;214(suppl 5):S497-S499.

48.

Pulmonary Dendritic Cell Subsets Shape the Respiratory Syncytial Virus-Specific CD8+ T Cell Immunodominance Hierarchy in Neonates.

Malloy AM, Ruckwardt TJ, Morabito KM, Lau-Kilby AW, Graham BS.

J Immunol. 2017 Jan 1;198(1):394-403. Epub 2016 Nov 28.

49.

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).

Crank MC, Wilson EM, Novik L, Enama ME, Hendel CS, Gu W, Nason MC, Bailer RT, Nabel GJ, McDermott AB, Mascola JR, Koup RA, Ledgerwood JE, Graham BS; VRC012 Study Team.

PLoS One. 2016 Nov 15;11(11):e0166393. doi: 10.1371/journal.pone.0166393. eCollection 2016.

50.

A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes.

Goo L, Dowd KA, Lin TY, Mascola JR, Graham BS, Ledgerwood JE, Pierson TC.

J Infect Dis. 2016 Nov 15;214(10):1487-1491. Epub 2016 Sep 21.

Supplemental Content

Loading ...
Support Center